227 related articles for article (PubMed ID: 26265015)
21. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
22. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
[TBL] [Abstract][Full Text] [Related]
23. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
24. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
25. Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Shalom G; Zisman D; Bitterman H; Harman-Boehm I; Greenberg-Dotan S; Dreiher J; Feldhamer I; Moser H; Hammerman A; Cohen Y; Cohen AD
JAMA Dermatol; 2015 May; 151(5):533-8. PubMed ID: 25797026
[TBL] [Abstract][Full Text] [Related]
26. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
27. OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.
Papp KA; Bourcier M; Poulin Y; Lynde CW; Gilbert M; Poulin-Costello M; Billen L; Isaila M
J Cutan Med Surg; 2018; 22(3):297-303. PubMed ID: 29466863
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
29. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.
Mori S; Yoshitama T; Hidaka T; Sakai F; Hasegawa M; Hashiba Y; Suematsu E; Tatsukawa H; Mizokami A; Yoshizawa S; Hirakata N; Ueki Y
PLoS One; 2017; 12(6):e0179179. PubMed ID: 28594905
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
[TBL] [Abstract][Full Text] [Related]
31. Biologic response modifiers and pediatric psoriasis.
Bellodi Schmidt F; Shah KN
Pediatr Dermatol; 2015; 32(3):303-20. PubMed ID: 25727936
[TBL] [Abstract][Full Text] [Related]
32. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
Qiang JK; Shahbaz A; Kim W; Marinas J; Greaves S; Yeung J
J Am Acad Dermatol; 2016 Jan; 74(1):176-7. PubMed ID: 26702799
[No Abstract] [Full Text] [Related]
34. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan.
Chen YJ; Wu CY; Chen TJ; Shen JL; Chu SY; Wang CB; Chang YT
J Am Acad Dermatol; 2011 Jul; 65(1):84-91. PubMed ID: 21458106
[TBL] [Abstract][Full Text] [Related]
35. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.
Paul CF; Ho VC; McGeown C; Christophers E; Schmidtmann B; Guillaume JC; Lamarque V; Dubertret L
J Invest Dermatol; 2003 Feb; 120(2):211-6. PubMed ID: 12542524
[TBL] [Abstract][Full Text] [Related]
36. Treatments for psoriasis and the risk of malignancy.
Patel RV; Clark LN; Lebwohl M; Weinberg JM
J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
[TBL] [Abstract][Full Text] [Related]
37. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
39. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
Kimball AB; Pariser D; Yamauchi PS; Menter A; Teller CF; Shi Y; Yong M; Creamer K; Hooper M; Aras G; Kricorian G; Gelfand JM
J Am Acad Dermatol; 2013 May; 68(5):756-64. PubMed ID: 23357569
[TBL] [Abstract][Full Text] [Related]
40. Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study.
Paradisi A; Didona B; Tabolli S; Ricci F; Sobrino L; Panebianco A; Abeni D
Eur J Dermatol; 2017 Aug; 27(4):359-362. PubMed ID: 28524053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
